Recorded fact · drug.trial_access

drug.trial_access for secukinumab

One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 5c69ae34 resolves to.

The record

Fact id	`5c69ae3474dd671eed74e706`
Entity	drug: secukinumab
Field	drug.trial_access
Source	clinicaltrials.gov
Read on	2026-11-07T06:34:32.466Z
Source version	clinicaltrials-api-2.0.5-data-2026-11-06T10:00:05
Method	api
Verification	machine_read
Licence	Terms and Conditions (last updated 2023-01-31) READ in full 2026-11-07: data free to all requesters; reuse allowed on conditions: attribute ClinicalTrials.gov, keep data current, display the date the registry processed the data, state any modifications; do not represent the data as other than a US Government database; no use of extracted email addresses for marketing; some records may carry third-party copyright (consult the submitter) and the data carry an international copyright outside the US. API rate guidance page UNREAD (JS page rendered no text 2026-11-07). AMBER because of the third-party copyright caveat on submitter text; counts and ids are safe, long free text is not reproduced. \| DISPLAY CONDITIONS (any page or delivery using this source): attribute ClinicalTrials.gov, show the registry processing date, state our modifications, never present as other than a US Government database, never use extracted emails for marketing.
Edition	2026-11, Merkle root `006ab9a329709cbe...`

This fact carries no verifying quote; its source is the dataset named above.

The value

{
 "ingredient": "SECUKINUMAB",
 "recruitingInterventionalCount": 11,
 "notYetRecruitingCount": 10,
 "byPhase": {
  "PHASE1": 2,
  "PHASE4": 5,
  "NA": 3,
  "PHASE2": 1
 },
 "trials": [
  {
   "nctId": "NCT07237594",
   "briefTitle": "IL-17 Blockade to Decrease irAEs (REPLAY)",
   "phase": [
    "PHASE1"
   ],
   "leadSponsor": "Duke University",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-06",
   "startDate": "2026-03-12",
   "conditions": [
    "Metastatic Melanoma"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07237594"
  },
  {
   "nctId": "NCT06751238",
   "briefTitle": "Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).",
   "phase": [
    "PHASE1"
   ],
   "leadSponsor": "Novartis Pharmaceuticals",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-13",
   "startDate": "2025-09-24",
   "conditions": [
    "Juvenile Psoriatic Arthritis"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06751238"
  },
  {
   "nctId": "NCT04638647",
   "briefTitle": "Secukinumab Open Label Roll-over Extension Protocol",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "Novartis Pharmaceuticals",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-13",
   "startDate": "2020-12-22",
   "conditions": [
    "Autoimmunity, Inflammation"
   ],
   "countries": [
    "United States",
    "Brazil",
    "Bulgaria",
    "China",
    "Colombia",
    "Czechia",
    "Greece",
    "Guatemala",
    "India",
    "Italy"
   ],
   "url": "https://clinicaltrials.gov/study/NCT04638647"
  },
  {
   "nctId": "NCT07489573",
   "briefTitle": "Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "Novartis Pharmaceuticals",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-09-09",
   "startDate": "2026-06-01",
   "conditions": [
    "Hidradenitis Suppurativa (HS)"
   ],
   "countries": [
    "China"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07489573"
  },
  {
   "nctId": "NCT06399432",
   "briefTitle": "Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors",
   "phase": [
    "NA"
   ],
   "leadSponsor": "University Hospitals Cleveland Medical Center",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-09-04",
   "startDate": "2022-10-18",
   "conditions": [
    "Psoriasis"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06399432"
  },
  {
   "nctId": "NCT07138898",
   "briefTitle": "Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "NYU Langone Health",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-07-09",
   "startDate": "2025-12-12",
   "conditions": [
    "Rheumatic Disease"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07138898"
  },
  {
   "nctId": "NCT06398106",
   "briefTitle": "Proactive TDM Versus Standard Use of Biologics in Psoriasis",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "University Hospital, Ghent",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-03-04",
   "startDate": "2024-12-20",
   "conditions": [
    "Psoriasis Vulgaris"
   ],
   "countries": [
    "Belgium"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06398106"
  },
  {
   "nctId": "NCT05303285",
   "briefTitle": "A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "Tongji Hospital",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-01-27",
   "startDate": "2024-06-14",
   "conditions": [
    "Ankylosing Spondylitis (AS)"
   ],
   "countries": [
    "China"
   ],
   "url": "https://clinicaltrials.gov/study/NCT05303285"
  },
  {
   "nctId": "NCT07149792",
   "briefTitle": "A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "Taichung Veterans General Hospital",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2025-09-02",
   "startDate": "2025-07-29",
   "conditions": [
    "Psoriasis",
    "Psoriasis Arthritis",
    "Biologics"
   ],
   "countries": [
    "Taiwan"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07149792"
  },
  {
   "nctId": "NCT06707246",
   "briefTitle": "A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients",
   "phase": [
    "NA"
   ],
   "leadSponsor": "Second Affiliated Hospital, Zhejiang University, School of Medicine",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2024-11-27",
   "startDate": "2024-12-15",
   "conditions": [
    "Hidradenitis Suppurativa"
   ],
   "countries": [
    "China"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06707246"
  },
  {
   "nctId": "NCT05503875",
   "briefTitle": "Immunoclassification of Psoriasis: a Strategy for Precision Medicine",
   "phase": [
    "NA"
   ],
   "leadSponsor": "Second Affiliated Hospital, Zhejiang University, School of Medicine",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2024-01-12",
   "startDate": "2023-01-01",
   "conditions": [
    "Immunoclassification",
    "Psoriasis"
   ],
   "countries": [
    "China"
   ],
   "url": "https://clinicaltrials.gov/study/NCT05503875"
  }
 ],
 "query": {
  "intr": "secukinumab",
  "filterOve
... (shortened here; the full value is in the JSON twin)

SHA-256 of the exact stored value: 0431691673509808571ebeb47493da636bf9fd1dcadf00fa051be3c505de75b0.

This fact as data (JSON) · Check an answer against its receipt · Licence

Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.